Quantcast

Latest AMD Stories

2014-07-09 08:28:58

First clinical trial of integrated approach underlines need for inclusion of behavior activation therapy in low vision rehabilitation SAN FRANCISCO, July 9, 2014 /PRNewswire-USNewswire/ -- The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD). The results of the study were published online today in Ophthalmology,...

2014-07-01 23:01:42

Diopsys® NOVA-ERG provides a way to discriminate between AMD and healthy eyes. Pine Brook, NJ (PRWEB) July 01, 2014 In a controlled clinical study, a team of researchers from New York Eye and Ear Infirmary concluded that test data from the Diopsys® NOVA-ERG vision test provides a way to discriminate both dry and wet Age-Related Macular Degeneration (AMD) eyes from healthy eyes. The study results published in a poster titled 'Steady State Pattern Electroretinography (ssPERG)...

2014-06-19 08:28:14

SOPHIA ANTIPOLIS, France, and SAN DIEGO, June 19, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes...

2014-06-12 23:09:39

Ophthalmologist Michael Tracy, MD of Carlsbad Eye Care describes new findings on potential eye dangers. San Diego, CA (PRWEB) June 12, 2014 A recent study by the American Academy of Ophthalmology has found a link between age-related macular degeneration (AMD) and medications for managing high blood pressure. According to the study, vasodilators are associated with a nearly 75% greater risk of developing AMD or other vision-threatening diseases. Carlsbad ophthalmologist Dr. Michael Tracy...

2014-06-11 04:21:59

TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO). The EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked,...

2014-06-05 12:30:20

LONDON, June 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Ophthalmic Devices, Diagnostics and Surgical Equipment: Global Marketshttp://www.reportbuyer.com/pharma_healthcare/medical_devices/ophthalmic_devices_diagnostics_surgical_equipment_global_markets.html INTRODUCTIONSTUDY GOALS AND OBJECTIVESThis BCC report, Ophthalmic Devices, Diagnostics and Surgical Equipment: Global Markets, provides a comprehensive description of conditions and diseases that...

2014-05-28 16:24:35

Major population study finds vasodilators may raise likelihood of age-related macular degeneration SAN FRANCISCO, May 28, 2014 /PRNewswire-USNewswire/ -- There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older,[1] according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology....

2014-05-08 09:24:07

Researchers have found that, contrary to previous clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla. The investigators used a strategy called "treat and extend" to conduct the study, in which the frequency of office visits and injections were tailored to each patient's...

2014-04-24 08:35:50

Renowned ophthalmic expert to provide critical guidance to MacuLogix HUMMELSTOWN, Pa., April 24, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced the appointment of Joan W. Miller, MD FARVO as a Clinical Advisor. Dr. Miller will provide MacuLogix with guidance on the development and commercialization of the Company's AdaptDx®, an advanced dark adaptometer used by eye care physicians to...

2014-04-22 12:30:18

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014 /PRNewswire/ -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.